New Life is pleased to announce the newest member of our team, Rajen Naidoo, M.D.
Dr. Naidoo has accepted the position of Chief Medical Officer and brings with him a wealth of knowledge in regenerative medicine.
A native of South Africa, Dr. Naidoo served under Nelson Mandela prior to pursuing his medical education at Yale University School of Medicine. Below are just a few of the credentials Rajen has gained during his career as a board-certified orthopedic surgeon:
- Biomedical Engineer
- Orthopedic Special Surgery of the Palm Beaches, Inc
- Assistant Professor of Orthopedic Surgery Mt Sinai School of Medicine
- Yale University School of Medicine
- CMO and Partner: World Biotech Regenerative Medical Group Ltd, Hong Kong
- Founding Partner Apollo Regenerative Solutions, LLC
- Scientist Collaborator: Harvard Medical School Dean Center for Tick-Borne Diseases
Dr. Naidoo will periodically be providing you updates of the exciting plans we have for New Life, including expanding our portfolio of products as well as our processing capabilities.
A few words from Dr. Naidoo:
“As doctors, we have been trained to have the clinical skills and compassion for our patients and therefore be the guardians of their wellbeing and advocates for patient safety. This includes the responsibility of ensuring that procedures we subject our patients to and medications we administer meet the highest standards of care. My one pure test is always “will we do the same for ourselves and loved ones?”
It behooves us to ensure the absolute safety of the products we use and to understand the rigorous testing and meticulous handling required prior to the administration of our products. Therefore, New Life is committed to a training program for its practitioner clients. As the CMO, I also committed to ensuring that every product passes an equally rigorous testing process and my pure test.
The COVID pandemic has changed all our lives as we are aware. The silver lining is that the many clinical studies from Wuhan, Beijing, Hong Kong, and Manila have raised the attention to the protective probability of stem cells in the lungs and modulation of the cytokine storm (comprehensive webinar available). Hence, this is an opportunity for us to further the technology and produce data which the FDA is requesting on the path to regulatory approval. I will be calling on many of you with proposals and protocols to partner with us in responsible data acquisition and clinical trials. We are committed to responsible and ethical science and we endeavor to contribute to the regulatory approval of our regenerative products.
I urge everyone to reinforce their good clinical practice in research and take a 6-hour online module which we will make available to you via New Life. This is required by the FDA for anyone involved in clinical research.
I hope that you all remain safe and healthy during this difficult time and practice the precautions and safety measures recommended by the CDC.”
My sincerest and warmest wishes,
Rajen Naidoo MD PhD
Chief Medical Officer
New Life Regenerative Medicine